ABS-201 in Androgenetic Alopecia

This market will resolve to YES if, by Dec. 31, 2026, 11:59 PM ET, Absci reports interim headline data in androgenetic alopecia patients showing at least one of the following for ABS-201: 1. A numerical Target Area Hair Count (TAHC) change from baseline greater than 0 in at least one ABS-201 dose group; 2. A placebo-adjusted TAHC difference greater than 0 in at least one ABS-201 dose group; 3. A quantified dose-response pattern in TAHC favoring ABS-201, supported by reported numerical TAHC values, changes, percentages, or placebo-adjusted differences across at least two ABS-201 dose groups. Statistical significance is not required. This market will resolve to NO if, by the deadline: 1. No interim headline clinical data is reported; 2. Interim data is reported, but no numerical TAHC data is disclosed; 3. TAHC is reported as flat or worse for all ABS-201 dose groups; 4. Only safety, tolerability, PK, PD, or immunogenicity data is reported, with no numerical hair-count efficacy data; 5. ABS-201 is paused, discontinued, or terminated before numerical TAHC data is reported. Vague statements such as "encouraging signal," "trend toward improvement," "biological activity," or "dose-response observed" are not sufficient for YES unless supported by numerical TAHC data. Resolution sources: official Absci press releases, SEC filings, official investor presentations, or ClinicalTrials.gov results.